QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
Log in
ASX:CDY

Cellmid Limited (CDY.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.19
MA: A$0.18
A$0.19
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cellmid Limited, a life sciences company, researches, develops, and commercializes diagnostic and therapeutic products for cancer and various chronic inflammatory conditions in Australia, the United States, and Japan. The company offers midkine, a driver and modulator of inflammatory diseases, including chronic inflammatory diseases and cancer; and focuses on blocking midkine, a protein for autoimmune disorders, chronic inflammation, osteoporosis, cardiovascular diseases, cancer, and neurodegenerative diseases. It also develops and sells over-the-counter products; and a range of FGF5 inhibitor hair growth products under the evolis, evolis Professional, Lexilis Hybrid, Jo-Ju RED, and Lexilis BLACK brands. In addition, the company sells SARS-CoV-2 antibody kits and PCR tests. It markets its products through retailers and wholesalers, as well as through a direct-to-consumer e-commerce platform. Cellmid Limited was incorporated in 2004 and is based in Sydney, Australia.

MarketRank

Overall MarketRank

0.81 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 2 9221 6830
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.48 million
Book ValueA$0.08 per share

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Receive CDY News and Ratings via Email

Sign-up to receive the latest news and ratings for CDY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cellmid Limited (CDY.AX) (ASX:CDY) Frequently Asked Questions

What stocks does MarketBeat like better than Cellmid Limited (CDY.AX)?

Wall Street analysts have given Cellmid Limited (CDY.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cellmid Limited (CDY.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Cellmid Limited (CDY.AX)'s earnings last quarter?

Cellmid Limited (CDY.AX) (ASX:CDY) announced its quarterly earnings results on Thursday, February, 21st. The company reported ($0.05) earnings per share for the quarter.
View Cellmid Limited (CDY.AX)'s earnings history
.

Who are some of Cellmid Limited (CDY.AX)'s key competitors?

What other stocks do shareholders of Cellmid Limited (CDY.AX) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellmid Limited (CDY.AX) investors own include Westgold Resources Limited (WGX.AX) (WGX) and Credit Intelligence Limited (CI1.AX) (CI1).

Who are Cellmid Limited (CDY.AX)'s key executives?

Cellmid Limited (CDY.AX)'s management team includes the following people:
  • Ms. Maria Halasz, CEO, MD & Exec. Director
  • Mr. Brian McGee, CEO of Advangen LLC
  • Mr. Koichiro Koike, Managing Director of Advangen Inc (Age 64, Pay $303.67k)
  • Mr. Dominic Burg, Chief Operating Officer
  • Dr. Graham Robertson, Head of R&D
  • Ms. Trish Frelan, Global Head of Marketing Advangen Pty Ltd
  • Mr. Lee Tamplin B.A., Company Sec.

What is Cellmid Limited (CDY.AX)'s stock symbol?

Cellmid Limited (CDY.AX) trades on the ASX under the ticker symbol "CDY."

How big of a company is Cellmid Limited (CDY.AX)?

Cellmid Limited (CDY.AX) has a market capitalization of $0.00 and generates $7.48 million in revenue each year.

What is Cellmid Limited (CDY.AX)'s official website?

The official website for Cellmid Limited (CDY.AX) is www.cellmid.com.au.

How can I contact Cellmid Limited (CDY.AX)?

The company can be reached via phone at 61 2 9221 6830.

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.